Bayer, NeuroCycle advance allergy treatment options animals

Bayer, NeuroCycle to advance allergy treatment options for animals

6:19 AM, 14th September 2018
License agreement between Bayer Animal Health and NeuroCycle Therapeutics.
From left: Douglas Hutchens, Head Drug Discovery, External Innovation and Chief Veterinary Officer (Bayer Animal Health), Jed Hubbs, CEO (NeuroCycle Therapeutics), Matthew Toczko, Secretary and COO, (NeuroCycle Therapeutics), Sabine Bongaerts, Head of Development (Bayer Animal Health)

MONHEIM, GERMANY: Bayer Animal Health GmbH and NeuroCycle Therapeutics Inc (NCT) have signed a global license agreement to advance innovative allergy treatment options for companion animals.

As part of the license agreement, Bayer will develop and commercialize novel compounds based on knowledge and intellectual property licensed and controlled by NCT.

Pet ownership is growing around the world and with that customers’ requirement for more effective and convenient treatment options. “At Bayer, we are committed to help pet owners improve the health and well-being of their animals. We know that allergies are among the most important health and well-being concerns for pet owners and veterinarians. The license agreement with NCT is a strong signal of our commitment to our customers around the world to address these concerns,” said Dr Sabine Bongaerts, head of development within Bayer Animal Health.

“Today’s agreement underlines our strategy to combine the know-how from creative start-up companies like NCT with opportunities derived from Bayer’s research. It is a major milestone on our way to complementing our portfolio with novel treatment options against allergic diseases for the companion animal sector. Now, we will focus on evolving these options from research and development to market maturity,” added Dr Douglas Hutchens, Bayer Animal Health’s head of drug discovery, external innovation & chief veterinary officer.

“Our goal is to maximize the humanitarian impact of our innovative technologies. This license agreement with Bayer Animal Health aligns with this goal by allowing our technology to be applied beyond our core focus on human health,” said Dr Jed Hubbs, NeuroCycle Therapeutics’ CEO.

© Worldofchemicals News

0 Comments

Login

Your Comments (Up to 2000 characters)
Please respect our community and the integrity of its participants. WOC reserves the right to moderate and approve your comment.

Related News


Brenntag acquires African distributor Desbro

ESSEN, GERMANY: Brenntag AG has entered into an agreement to acquire the Desbro Group in Kenya, Tanzania, Uganda and the UAE. The company, headquarter ...

Read more
Oil up over 2 pc on concerns over Iran, slower US output growth

NEW YORK, US: Oil prices rose more than 2 percent on Tuesday as US sanctions squeezed Iranian crude exports and after US crude oil production in 2019 ...

Read more
Invista to increase nylon 6,6 polymer capacity

KANSAS, US: Invista plans to add 40,000 tons of nylon 6,6 polymer capacity at its current 150,000-ton polymer plant at the Shanghai Chemical Industry ...

Read more
Covestro develops new super-plastic with positive eco-balance

LEVERKUSEN, GERMANY: Covestro AG and its partners have developed a high-performance thermoplastic (HPT) that could be used in many industries in the f ...

Read more
Russia's Sibur in talks with banks about possible IPO

MOSCOW, RUSSIA: Russian petrochemical producer Sibur has begun talks with banks about a possible initial public offering, CNBC cited Sibur’s CEO ...

Read more
K+S temporarily shuts Hattorf site due to drought

KASSEL, GERMANY: K+S AG said that due to the persistent severe drought, the water level in the Werra river remains at an exceptionally low level. Ther ...

Read more
www.worldofchemicals.com uses cookies to ensure that we give you the best experience on our website. By using this site, you agree to our Privacy Policy and our Terms of Use. X